Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2021-07-20 Transaction in Own Shar…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version agrégée)
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres réalisées du 12 au 16 Juillet 2021" (Declaration of transactions on own shares carried out from July 12 to 16, 2021). This explicitly details the company's activity regarding buying back or selling its own shares during a specific period. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The document is a detailed report of these transactions, not just an announcement of a report's publication.
2021-07-20 French
Inside Information / Other news releases
M&A Activity Classification · 1% confidence The document is a press release announcing a new exclusive worldwide licensing agreement between Ipsen and IRLAB for the development of a Parkinson's disease treatment. It details the financial terms, the nature of the partnership, and provides background information on the companies involved. This type of corporate announcement regarding M&A or licensing activity is classified as M&A Activity (TAR).
2021-07-15 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated July 15, 2021, announcing a global exclusive license agreement between Ipsen and IRLAB for the development and commercialization of mesdopetam for Parkinson's disease. It details financial terms (upfront payment, milestones, royalties) and includes standard sections like 'About Ipsen', 'About IRLAB', and 'Forward-Looking Statements'. This type of announcement, detailing a significant corporate transaction (licensing/partnership) and financial implications, fits best under the 'Capital/Financing Update' (CAP) category, as it involves a major financial arrangement and rights transfer, although it is not a direct capital raise. However, given the options, 'CAP' is the closest fit for a major deal structure announcement involving significant financial consideration and future revenue streams, or potentially 'RNS' as a general regulatory announcement. Since it details the financial structure of a major deal, 'CAP' is selected over the generic 'RNS'. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). The text explicitly states: 'Cette annonce est une information qu'IRLAB Therapeutics est obligée de rendre publique conformément à la réglementation européenne sur les abus de marché.' This strongly suggests a mandatory regulatory disclosure, but the content is highly specific to a licensing deal, making CAP more descriptive than the fallback RNS.
2021-07-15 French
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Transaction in Own Shares Classification · 1% confidence The document explicitly details 'Disclosure transaction in own shares' over a specific period (05/07/2021 to 09/07/2021) and presents aggregated data on volume and price, which is characteristic of a report detailing share repurchase or issuance activity. This directly matches the definition for 'Transaction in Own Shares' (Code: POS). The document is not a general announcement (RPA/RNS) as it contains the detailed transaction data itself, nor is it a management change (MANG) or a general financial report (10-K/IR).
2021-07-13 English
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version agrégée)
Transaction in Own Shares Classification · 1% confidence The document is titled "Déclaration des transactions sur actions propres réalisées du 05 au 09 Juillet 2021" (Declaration of transactions on own shares carried out from July 5 to 9, 2021). It contains detailed tables showing the volume and price of shares transacted by the issuer (IPSEN) on various markets during that specific period. This content directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category.
2021-07-13 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Capital/Financing Update Classification · 1% confidence The document is titled "Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF" and provides specific figures regarding shares and cash held in a liquidity account as of June 30, 2021, along with transaction volumes during the first half of the year. This content relates to the management of company assets or financing arrangements, specifically concerning liquidity provision. While it mentions a 'Half-year statement,' the core content is a specific disclosure about a liquidity agreement, which is a type of financing or capital management activity. It is not a comprehensive Interim/Quarterly Report (IR) as it lacks full financial statements. It is most closely aligned with Capital/Financing Update (CAP) as it details the status and activity of a financing/liquidity agreement. Given the specific nature of reporting on liquidity agreements, CAP is the most appropriate fit over general regulatory filings (RNS).
2021-07-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.